Erythrocyte-derived vesicles for circulating tumor cell capture and specific tumor imaging

Chen, Ming; Liu, Ao; Chen, Bei; Zhu, Delan; Deng, Fangfang; Ji, Liwei; Chen, Li-Ben; Huang, Huiming; Fu, Yourong; Liu, Wei; Wang, Xinghuan

doi:10.1039/c9nr01805k

Cited by 15 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fludarabine-loaded RBCs were administered to kill the persistent chronically HIV-1 infected macrophages in circulation, that selectively killed infected macrophages and showed significant efficacy (>98%) in single exposure which lasted for 4 weeks ( Magnani et al, 2003 ). Researchers have also reported RBC coated nano sponges that have shown detoxifying effects in organophosphate poisoning ( Chen et al, 2019 ). The same group has also reported RBC coated nanogels and RBC coated sponges for antibiotic delivery in methicillin resistant Staphylococcus aureus (MRSA) infections ( Chen et al, 2019a ) ( Zhang Z. et al, 2017 ).…”

Section: Applications Of Red Blood Cell Membrane-derived Systemsmentioning

confidence: 99%

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

et al. 2022

View full text Add to dashboard Cite

Red Blood Cells (RBCs)-derived particles are an emerging group of novel drug delivery systems. The natural attributes of RBCs make them potential candidates for use as a drug carrier or nanoparticle camouflaging material as they are innately biocompatible. RBCs have been studied for multiple decades in drug delivery applications but their evolution in the clinical arena are considerably slower. They have been garnering attention for the unique capability of conserving their membrane proteins post fabrication that help them to stay non-immunogenic in the biological environment prolonging their circulation time and improving therapeutic efficiency. In this review, we discuss about the synthesis, significance, and various biomedical applications of the above-mentioned classes of engineered RBCs. This article is focused on the current state of clinical translation and the analysis of the hindrances associated with the transition from lab to clinic applications.

show abstract

Section: Applications Of Red Blood Cell Membrane-derived Systemsmentioning

confidence: 99%

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A recent emerging novel engineering strategy is the fabrication of biomimetic nanoparticles that combine synthetic nanomaterials with natural biomaterials, such as the membranes of leukocytes (43), RBCs (44) and platelets (45). A fluidic and multivalent engineered nanointerface decorating a microfluidic chip with aptamer-functionalized leukocyte membrane nanovesicles has been described (46).…”

Section: Application Of Nanomaterials For Isolation and Detection Ofmentioning

confidence: 99%

Detection of circulating tumor cells: Advances and critical concerns (Review)

Zang

2021

Oncol Lett

View full text Add to dashboard Cite

Metastasis is the main cause of cancer-related death and the major challenge in cancer treatment. Cancer cells in circulation are termed circulating tumor cells (CTCs). Primary tumor metastasis is likely due to CTCs released into the bloodstream. These CTCs extravasate and form fatal metastases in different organs. Analyses of CTCs are clarifying the biological understanding of metastatic cancers. These data are also helpful to monitor disease progression and to inform the development of personalized cancer treatment-based liquid biopsy. However, CTCs are a rare cell population with 1-10 CTCs per ml and are difficult to isolate from blood. Numerous approaches to detect CTCs have been developed based on the physical and biological properties of the cells. The present review summarizes the progress made in detecting CTCs. Contents 1. Introduction 2. Novel materials for enrichment and detection of CTCs 3. Novel technologies for isolation and detection of CTCs 4. Discussion

show abstract

“…Achieving Tumor targeting and fluorescence imaging simultaneously. FR CRC/BC > 95 > 90 – [ 27 ] Fluorescent probe FA functionalized terbium-doped dendritic fibrous nanosilica fluorescence spectrometry. Fluorescence microscopy and flow cytometry were utilized to verify the uptake of the fluorescent probe with FR-positive tumor cells.…”

Section: Ctc Enrichment and Identificationmentioning

confidence: 99%

“…The immune escape mechanism of natural cells greatly reduces nonspecific binding, showing their potential as highly specific CTC capture materials. Chen et al engineered an FA modified erythrocyte-derived nanovesicle as a tumor-targeting molecules [ 27 ]. They achieved a high capture efficiency (> 90%) in whole blood, while magnetic-activated cell sorting (MACS) reached only 50%.…”

Section: Ctc Enrichment and Identificationmentioning

confidence: 99%

Detection and clinical significance of circulating tumor cells in colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Histopathological examination (biopsy) is the “gold standard” for the diagnosis of colorectal cancer (CRC). However, biopsy is an invasive method, and due to the temporal and spatial heterogeneity of the tumor, a single biopsy cannot reveal the comprehensive biological characteristics and dynamic changes of the tumor. Therefore, there is a need for new biomarkers to improve CRC diagnosis and to monitor and treat CRC patients. Numerous studies have shown that “liquid biopsy” is a promising minimally invasive method for early CRC detection. A liquid biopsy mainly samples circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA (miRNA) and extracellular vesicles (EVs). CTCs are malignant cells that are shed from the primary tumors and/or metastases into the peripheral circulation. CTCs carry information on both primary tumors and metastases that can reflect dynamic changes in tumors in a timely manner. As a promising biomarker, CTCs can be used for early disease detection, treatment response and disease progression evaluation, disease mechanism elucidation, and therapeutic target identification for drug development. This review will discuss currently available technologies for plasma CTC isolation and detection, their utility in the management of CRC patients and future research directions.

show abstract

Erythrocyte-derived vesicles for circulating tumor cell capture and specific tumor imaging

Abstract: The precise diagnosis of cancer remains a great challenge; therefore, it is our research interest to develop safe, tumor-specific reagents.

Cited by 15 publications

References 38 publications

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation

Detection of circulating tumor cells: Advances and critical concerns (Review)

Detection and clinical significance of circulating tumor cells in colorectal cancer

Contact Info

Product

Resources

About